Interferon Gamma-1B for Candida Blood Infection
(HDM-FUN Cand Trial)
Trial Summary
What is the purpose of this trial?
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have been treated with certain immune-related therapies or antifungal treatments recently, you may not be eligible to participate.
What evidence supports the effectiveness of the drug Interferon Gamma-1B for treating Candida blood infections?
Research shows that Interferon Gamma-1B can enhance the body's immune response against fungal infections like Candida by activating certain immune cells. In animal studies, it has been effective in fighting Candida infections, although its effectiveness may be limited in cases of severely weakened immune systems.12345
Is Interferon Gamma-1B generally safe for human use?
Interferon Gamma-1B has been studied in humans for conditions like AIDS-related cryptococcal meningitis and was found to be well tolerated, meaning it did not cause significant side effects. This suggests it is generally safe for human use, although specific safety data for Candida blood infections is not available.13456
How does the drug Interferon Gamma-1B work differently for Candida blood infection?
Interferon Gamma-1B is unique because it boosts the body's immune response by activating certain immune cells to better fight off Candida infections. Unlike standard antifungal drugs, it enhances the body's natural defenses, particularly by increasing the activity of cells that kill the fungus.13578
Research Team
Frank vd Veerdonk, Dr.
Principal Investigator
Radboud University Medical Center
Eligibility Criteria
Adults with a recent Candida blood infection confirmed by a positive culture, showing signs of infection like fever or low blood pressure, and not severely ill to survive less than 24 hours. They must consent to the study (or have a legal representative do so) and agree to use contraception if applicable. Excluded are those with severe liver failure, history of seizures, recent immunological treatments, pregnant or lactating women, failed prior antifungal therapy for this infection.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rIFN-y immunotherapy, subcutaneous dose of 100 microgram thrice weekly for two weeks or until hospital discharge, in addition to standard of care
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Interferon Gamma-1B
Interferon Gamma-1B is already approved in United States for the following indications:
- Chronic granulomatous disease
- Severe, malignant osteopetrosis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Radboud University
Lead Sponsor
Radboud University Medical Center
Lead Sponsor
Horizon 2020 - European Commission
Collaborator